A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity Hospital, Basel, Switzerland

About this trial

To assess the feasibility of donor-derived interferon (IFN)-γ positive select-ed virus-specific T-cells using the cytokine capture system® (CCS) and the safety of subsequent infusion in recipients of hematopoietic stem cell transplantation (HSCT) with treatment refractory post-transplant viral infections. The CCS has already been successfully used in clinical studies in Germany and United Kingdom (UK).

Eligibility criteria

Qualifiers

Adults > 18 years of age

Undergone allogeneic HSCT

Written informed consent

Antiviral treatment with cidofovir for at least 7 days

Disqualifiers

graft-versus-host disease (GVHD) > grade 2 at the time point of planned infusion

Known allergy to iron-dextran or murine antibodies

Trial design

Treatments tested in this trial

  • IFN-γ positive selected T-cells

Treatment groups

30 Participants
are divided into 1 treatment group